Management of fetuses with apparent normal growth and abnormal cerebroplacental ratio: A risk-based approach near term

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Khalil, Asma
Grups d'Investigació
Abstract
Introduction: Cerebroplacental ratio (CPR) has been shown to be an independent predictor of adverse perinatal outcome at term and a marker of failure to reach the growth potential (FRGP) regardless of fetal size, being abnormal in compromised fetuses with birthweight above the 10th centile. The main aim of this study was to propose a risk-based approach for the management of pregnancies with normal estimated fetal weight (EFW) and abnormal CPR near term.Material and methods: This was a retrospective study of 943 pregnancies, that underwent an ultrasound evaluation of EFW and CPR at or beyond 34 weeks. CPR values were converted into multiples of the median (MoM) and EFW into centiles according to local references. Pregnancies were then divided into four groups: normal fetuses (defined as EFW >= 10th centile and CPR >= 0.6765 MoM), small for gestational age (EFW <10th centile and CPR >= 0.6765 MoM), fetal growth restriction (EFW <10th centile and CPR <0.6765 MoM), and fetuses with apparent normal growth (EFW >= 10th centile) and abnormal CPR (<0.6765 MoM), that present FRGP. Intrapartum fetal compromise (IFC) was defined as an abnormal intrapartum cardiotocogram or pH requiring cesarean delivery. Risk comparisons were performed among the four groups, based on the different frequencies of IFC. The risks of IFC were subsequently extrapolated into a gestational age scale, defining the optimal gestation to plan the birth for each of the four groups.Results: Fetal growth restriction was the group with the highest frequency of IFC followed by FRGP, small for gestational age, and normal groups. The "a priori" risks of the fetal growth restriction and normal groups were used to determine the limits of two scales. One defining the IFC risk and the other defining the appropriate gestational age for delivery. Extrapolation of the risk between both scales placed the optimal gestational age for delivery at 39 weeks of gestation in the case of FRGP and at 40 weeks in the case of small for gestational age.Conclusions: Fetuses near term may be evaluated according to the CPR and EFW defining four groups that present a progressive risk of IFC. Fetuses in pregnancies complicated by FRGP are likely to benefit from being delivered at 39 weeks of gestation.
© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Dades de la publicació
- ISSN/ISSNe:
- 0001-6349, 1600-0412
- Tipus:
- Article
- Pàgines:
- 334-341
- DOI:
- 10.1111/aogs.14732
- PubMed:
- 38050342
- Factor d'Impacte:
- 1,232 SCImago ℠
- Quartil:
- Q1 SCImago ℠
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA Wiley-Blackwell
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Keywords
- adverse perinatal outcome, cerebroplacental ratio, ductus venosus Doppler, failure to reach growth potential, fetal Doppler, fetal growth restriction, middle cerebral artery Doppler, small baby, small for gestational age, umbilical artery doppler
Projectes associats
UTILIDAD DEL TRATAMIENTO TOCOLITICO DE MANTENIMIENTO EN EL MANEJO DE LA AMENAZA DE PARTO PREMATURO (APP)
Investigador Principal: MÁXIMO VENTO TORRES
EC11-246 . 2012
RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO
Investigador Principal: MÁXIMO VENTO TORRES
RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
PAPEL DEL FACTOR DE CRECIMIENTO PLACENTARIO EN EL MANEJO DE LA PREECLAMPSIA NO SEVERA: ESTUDIO ALEATORIZADO
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
PI15/01935 . INSTITUTO DE SALUD CARLOS III . 2016
Iplacenta. innovation in pacenta modelling for maternal and fetal health.
Investigador Principal: JOSÉ MORALES ROSELLÓ
765274 . COMISION EUROPEA . 2018
ENSAYO MULTICÉNTRICO, ABIERTO, ALEATORIZADO, DE DOSIS ÚNICA, CONTROLADO, DE XOMA 213 ADMINISTRADO POR VÍA INTRAVENOSA A MUJERES DESPUÉS DEL PARTO PARA LA SUPRESIÓN DE LA LACTANCIA.
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
X213220
ENSAYO EN FASE III, ALEATORIZADO, DOBLE CIEGO O CON ENMASCARAMIENTO PARA EL OBSERVADOR, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA VACUNA DE SUBUNIDAD F PREFUSIÓN CONTRA EL VIRUS RESPIRATORIO SINCITIAL (VRS) EN LACTANTES NACIDOS D E MUJERES VACUNADAS DURANTE EL EMBARAZO
Investigador Principal: EMILIO MONTEAGUDO MONTESINOS
C3671008 . 2020
ESTUDIO FASE 2/3 CONTROLADO CON PLACEBO, ALEATORIZADO, CEGADO PARA EL OBSERVADOR, PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA INMUNOGENICIDAD DE UNA VACUNA CANDIDATA DE ARN (BNT162B2) DEL SARS-COV-2, CONTRA COVID-19 EN MUJERES EMBARAZADAS SANAS DE 18 AÑOS DE EDAD Y MAYORES.
Investigador Principal: VICENTE JOSE DIAGO ALMELA
C4591015 . 2021
EVALUACIÓN DE LA EFICACIA DEL USO DE CLORHEXIDINA DURANTE EL PRIMER TRIMESTRE COMO REGULADOR DE LA MICROBIOTA VAGINAL EN LA REDUCCIÓN DE PARTO PREMATURO.
Investigador Principal: JOSÉ MORALES ROSELLÓ
PLUVA . 2021
Comparison of maternal-fetal outcomes among unvaccinated and vaccinated pregnant women with Covid-19.
Investigador Principal: ALICIA MARTÍNEZ VAREA
CoVaGest . 2022
Elaboración de un algoritmo de predicción de parto tras inducción basado en criterios clínicos, epidemiológicos y ecográficos.
Investigador Principal: JOSÉ MORALES ROSELLÓ
Prepain . 2023